Rune Tønnesen, Kristian Buch, P. Hovind, L. T. Jensen, P. Schwarz
Objective Our study aimed to investigate the effect of vitamin D supplementation on blood pressure in vitamin D insufficient young volunteers compared to an age matched control group with sufficient levels of vitamin D. Secondarily we aimed to evaluate the effect of vitamin D supplementation on the RAAS and sympathetic nervous system. Design Single centre, Randomised controlled Trial. of Range 2.4) mmHg (p = 0.009), diastolic BP (daytime) decreased -4.5 (2.1) mmHg (p = 0.03), norepinephrine decreased -0.80 (0.21) nmol/L, (p = 0.0002). There was no effect of vitamin D supplementation on night time systolic or diastolic BP, and no effect on angiotensinogen, renin, angiotensin (I+II), aldosterone or epinephrine. We observed that 180 days of vitamin D supplementation in normal youngsters with insufficient vitamin D significantly lowered systolic and diastolic BP during daytime. Vitamin D supplementation also significantly lowered circulating norepinephrine. Nothing happened in the control group with normal vitamin D. Hence, it is tempting to conclude that vitamin D acts on BP through SNS as no changes were observed in the RAAS.
{"title":"Blood Pressure in Healthy Youngsters is modified by Vitamin-D Supplementation","authors":"Rune Tønnesen, Kristian Buch, P. Hovind, L. T. Jensen, P. Schwarz","doi":"10.31038/edmj.2019325","DOIUrl":"https://doi.org/10.31038/edmj.2019325","url":null,"abstract":"Objective Our study aimed to investigate the effect of vitamin D supplementation on blood pressure in vitamin D insufficient young volunteers compared to an age matched control group with sufficient levels of vitamin D. Secondarily we aimed to evaluate the effect of vitamin D supplementation on the RAAS and sympathetic nervous system. Design Single centre, Randomised controlled Trial. of Range 2.4) mmHg (p = 0.009), diastolic BP (daytime) decreased -4.5 (2.1) mmHg (p = 0.03), norepinephrine decreased -0.80 (0.21) nmol/L, (p = 0.0002). There was no effect of vitamin D supplementation on night time systolic or diastolic BP, and no effect on angiotensinogen, renin, angiotensin (I+II), aldosterone or epinephrine. We observed that 180 days of vitamin D supplementation in normal youngsters with insufficient vitamin D significantly lowered systolic and diastolic BP during daytime. Vitamin D supplementation also significantly lowered circulating norepinephrine. Nothing happened in the control group with normal vitamin D. Hence, it is tempting to conclude that vitamin D acts on BP through SNS as no changes were observed in the RAAS.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41422836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Reg`Activ Cholesterol Positive Effects in Asymptomatic Volunteers with Borderline Values of Cardio-Metabolic Risk Factors are Sustainable in Long-Term Run","authors":"","doi":"10.31038/edmj.2019324","DOIUrl":"https://doi.org/10.31038/edmj.2019324","url":null,"abstract":"","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41371088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Sigamani, Sanjaya Chauhan, G. Vikneswaran, Anju Joseph, Arun Kumar, KG Padma, Sandeep Kumar, Gupta, S. Tiwari, S. Kannan, Haleh Roohi, Leva Samimi, Prathipati Philip, C. Pidathala
Background: Current therapeutics do not provide optimized care in early stage type 2 diabetes and there is no established treatment for prediabetes. We did a randomised trial to assess the efficacy and safety of a popular Ayush product, Sugar Balance ® (sugar balance) in patients with newly diagnosed type 2 diabetes and prediabetes. Methods: In this multicentre, double blind placebo-controlled trial, we randomly assigned (1: 1) eligible participants, 30 years of age or older, of either gender and diagnosed with type 2 diabetes (HbA1c ≥ 6.5%) or prediabetes (FPG ≥ 5.6 mmol/L). We used computer-generated ramdomisation, stratified by type of diagnosis (prediabetes or diabetes). Active recipients were to receive 250 mg capsules containing 3 Organic certified whole herbs : Coccinia indica, Bougainvillea spectabilis and Madagascar periwinkle (sadabahar). The recommended dose was 2 capsules twice daily. The primary outcome was ≥0.5% reduction in HbA 1c for type 2 diabetes subjects and an increased incidence of normalization in impaired fasting blood glucose for prediabetes subjects at 6 months after randomization. The primary analysis included all subjects who received the allocated intervention and had 1 follow up visit after randomisation. All subjects received standard life style recommendations for diet and exercise. Type 2 diabetes subjects were allowed to be on biguanides (metformin) of their choice. This trial is registered with ClinicalTrials.gov, number NCT02866539 and clinical trials registry of India, number CTRI/2016/11/007435, and is completed. Findings: Between December 14 th 2016 and 28 th August 2017, 122 subjects were randomly assigned to active sugar balance (n=61) or matching placebo (n=61), of whom one subject (assigned to placebo) did not receive the allocated intervention. All follow up was completed on 16 th December 2017. At 6 months type 2 diabetes subjects allocated to active arm had a mean reduction of HbA 1c of -0.52% versus -0.43% among placebo arm (difference of -0.09% 95% CI -0.1705 - -0.0095). 13 (52%) versus 4 (15.4%) prediabetes subjects receiving the polyherbal achieved normalization of impaired fasting glycaemia (<100 mg/dl) (difference of 36.6% 95% CI 10.683 - 56.805). None of the study participants experienced significant hypoglycemia or significant changes in their safety clinical biochemistry parameters on therapy. Conclusions: Sugar Balance promises to be effective and safe supplement for type 2 diabetes subjects to achieve a better optimization of HbA 1c when taken along with standard dose of metformin and for prediabetes subjects to achieve their target fasting blood sugars with diet and exercise.
{"title":"A Polyherbal Indian System of Medicine (Ayush) Preparation for Optimization of Glycemic Control in Newly Diagnosed Type 2 Diabetes and Prediabetes; A Multicenter, Randomised, Double-Blind, Placebo- Controlled Trial","authors":"A. Sigamani, Sanjaya Chauhan, G. Vikneswaran, Anju Joseph, Arun Kumar, KG Padma, Sandeep Kumar, Gupta, S. Tiwari, S. Kannan, Haleh Roohi, Leva Samimi, Prathipati Philip, C. Pidathala","doi":"10.31038/edmj.2019322","DOIUrl":"https://doi.org/10.31038/edmj.2019322","url":null,"abstract":"Background: Current therapeutics do not provide optimized care in early stage type 2 diabetes and there is no established treatment for prediabetes. We did a randomised trial to assess the efficacy and safety of a popular Ayush product, Sugar Balance ® (sugar balance) in patients with newly diagnosed type 2 diabetes and prediabetes. Methods: In this multicentre, double blind placebo-controlled trial, we randomly assigned (1: 1) eligible participants, 30 years of age or older, of either gender and diagnosed with type 2 diabetes (HbA1c ≥ 6.5%) or prediabetes (FPG ≥ 5.6 mmol/L). We used computer-generated ramdomisation, stratified by type of diagnosis (prediabetes or diabetes). Active recipients were to receive 250 mg capsules containing 3 Organic certified whole herbs : Coccinia indica, Bougainvillea spectabilis and Madagascar periwinkle (sadabahar). The recommended dose was 2 capsules twice daily. The primary outcome was ≥0.5% reduction in HbA 1c for type 2 diabetes subjects and an increased incidence of normalization in impaired fasting blood glucose for prediabetes subjects at 6 months after randomization. The primary analysis included all subjects who received the allocated intervention and had 1 follow up visit after randomisation. All subjects received standard life style recommendations for diet and exercise. Type 2 diabetes subjects were allowed to be on biguanides (metformin) of their choice. This trial is registered with ClinicalTrials.gov, number NCT02866539 and clinical trials registry of India, number CTRI/2016/11/007435, and is completed. Findings: Between December 14 th 2016 and 28 th August 2017, 122 subjects were randomly assigned to active sugar balance (n=61) or matching placebo (n=61), of whom one subject (assigned to placebo) did not receive the allocated intervention. All follow up was completed on 16 th December 2017. At 6 months type 2 diabetes subjects allocated to active arm had a mean reduction of HbA 1c of -0.52% versus -0.43% among placebo arm (difference of -0.09% 95% CI -0.1705 - -0.0095). 13 (52%) versus 4 (15.4%) prediabetes subjects receiving the polyherbal achieved normalization of impaired fasting glycaemia (<100 mg/dl) (difference of 36.6% 95% CI 10.683 - 56.805). None of the study participants experienced significant hypoglycemia or significant changes in their safety clinical biochemistry parameters on therapy. Conclusions: Sugar Balance promises to be effective and safe supplement for type 2 diabetes subjects to achieve a better optimization of HbA 1c when taken along with standard dose of metformin and for prediabetes subjects to achieve their target fasting blood sugars with diet and exercise.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46265570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
De Lucio, Capretti Camilla, Scarcella Simone, Damiano
OBJECTIVE: Several studies have investigated the role of cranberry extract and D-mannose in the prevention of recurrent urinary tract infections (UTIs). The aim of this preliminary study was to test whether the use of a new dietary supplement (UROIAL TM sachets) containing cranberry extracts (S&R PACs), D-mannose, hyaluronic Acid and Glucosamine Chondroitin may reduce the incidence of episodes of cystitis and improve urinary symptoms. METHODS: In this prospective comparative study, 40 women with an acute diagnosis of cystitis received a single sachet of Fosfomycin Tromethamine (3gr). The subjects were then randomly assigned to two groups: Group A: 20 women were given UROIAL TM , 2 sachet per day during the first 7 days, then 1 sachet per day for two weeks; Group B: 20 women did not receive any treatment to serve as a control group. RESULTS: The results of the present study showed a complete remission of urinary symptoms in 37 women, a slight decrease in urinary symptoms was observed in 2 subjects, whereas 1 woman who stopped the treatment was considered a drop-out. Patients in Group A had a lower incidence of episodes of recurrent cystitis during treatment and follow-up; urine samples had significantly lower median bacterial load compared to baseline as well as a symptomatic relief was reported in treated subjects despite the control group. DISCUSSION: Several studies have investigated and demonstrated the role of cranberry extracts in the prevention of recurrent urinary tract infections (UTIs), on different selected subpopulations and even at increased risk of UTI. Even the use of D-mannose, a natural sugar has proven to have clinical benefit, although clinical data is limited. A randomized placebo-controlled non-blinded clinical trial has shown that a daily dose of 2 g d-mannose was superior to placebo in preventing UTI. Mannose receptors are found on uroepithelial cells lining the urinary tract they constitute the protective mucopolysaccharide layer of the bladder. The mechanism of action involves binding of the mannose receptors to E. coli pili, thus preventing both adhesion to and invasion of urothelial cells. The interaction between mannose molecules and E. coli bacteria can then be washed away with urine voiding. CONCLUSIONS: Our data indicate that the addition of GAGs (hyaluronic acid and chondroitin sulfate) to cranberry/D-Mannose containing products could represent a valid novel therapeutic approach for the treatment and/or prophylaxis of cystitis.
{"title":"Effects of a New Combination of Cranberry Extracts, D-Mannose and GAGs for the Management of Uncomplicated Urinary Tract Infection","authors":"De Lucio, Capretti Camilla, Scarcella Simone, Damiano","doi":"10.31038/edmj.2019315","DOIUrl":"https://doi.org/10.31038/edmj.2019315","url":null,"abstract":"OBJECTIVE: Several studies have investigated the role of cranberry extract and D-mannose in the prevention of recurrent urinary tract infections (UTIs). The aim of this preliminary study was to test whether the use of a new dietary supplement (UROIAL TM sachets) containing cranberry extracts (S&R PACs), D-mannose, hyaluronic Acid and Glucosamine Chondroitin may reduce the incidence of episodes of cystitis and improve urinary symptoms. METHODS: In this prospective comparative study, 40 women with an acute diagnosis of cystitis received a single sachet of Fosfomycin Tromethamine (3gr). The subjects were then randomly assigned to two groups: Group A: 20 women were given UROIAL TM , 2 sachet per day during the first 7 days, then 1 sachet per day for two weeks; Group B: 20 women did not receive any treatment to serve as a control group. RESULTS: The results of the present study showed a complete remission of urinary symptoms in 37 women, a slight decrease in urinary symptoms was observed in 2 subjects, whereas 1 woman who stopped the treatment was considered a drop-out. Patients in Group A had a lower incidence of episodes of recurrent cystitis during treatment and follow-up; urine samples had significantly lower median bacterial load compared to baseline as well as a symptomatic relief was reported in treated subjects despite the control group. DISCUSSION: Several studies have investigated and demonstrated the role of cranberry extracts in the prevention of recurrent urinary tract infections (UTIs), on different selected subpopulations and even at increased risk of UTI. Even the use of D-mannose, a natural sugar has proven to have clinical benefit, although clinical data is limited. A randomized placebo-controlled non-blinded clinical trial has shown that a daily dose of 2 g d-mannose was superior to placebo in preventing UTI. Mannose receptors are found on uroepithelial cells lining the urinary tract they constitute the protective mucopolysaccharide layer of the bladder. The mechanism of action involves binding of the mannose receptors to E. coli pili, thus preventing both adhesion to and invasion of urothelial cells. The interaction between mannose molecules and E. coli bacteria can then be washed away with urine voiding. CONCLUSIONS: Our data indicate that the addition of GAGs (hyaluronic acid and chondroitin sulfate) to cranberry/D-Mannose containing products could represent a valid novel therapeutic approach for the treatment and/or prophylaxis of cystitis.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49365338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dalteparin Induced Skin Necrosis in a Patient Following Pelvic Floor Repair Surgery","authors":"","doi":"10.31038/edmj.2019321","DOIUrl":"https://doi.org/10.31038/edmj.2019321","url":null,"abstract":"","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48899940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mark B Zimering, John J Shin, Jennifer D Zaitz, Elkin A Nunez, Andrew G Gianoukakis
Purpose: To report a case of orbital fat expansion leading to globe prolapse in a Graves' disease patient undergoing high-dose glucocorticoid therapy. To evaluate the growth factor receptor specificities of plasma autoantibodies in Graves' disease patients who exhibited contrasting subtypes of thyroid-associated ophthalmopathy, i.e. orbital fat expansion-type vs. infiltrative.
Methods: Sera from Graves' orbitopathy and control patients with or without Graves' disease were subjected to protein-A affinity chromatography to obtain immunoglobulin G. A (1/50th to 1/1600th) range in dilutions of the protein-A eluate fraction was incubated for four days at 37 degrees C with bovine pulmonary artery endothelial cells to test for endothelial cell inhibition or stimulation. Growth stimulatory autoantibodies were co-incubated with specific neutralizing anti-insulin like growth factor 1 receptor antibodies or anti-basic fibroblast growth factor antibodies to assess autoantibody specificity in contrasting Graves' orbitopathy subtypes.
Results: We observed increased mean endothelial cell growth promoting activity in the protein-A eluates of serum from eighteen patients with active Graves' disease (117 ± 28%, n = 18) compared to mean endothelial cell activity (89 ± 10%, n = 13, P = 0.003) in thirteen adults without Graves' disease. The protein-A eluate fraction in acute infiltrative-type Graves' orbitopathy contained a high titer (> 1:1000) of endothelial cell stimulatory activity which was significantly neutralized by specific monoclonal anti-human insulin-like growth factor 1 receptor antibodies. The protein-A eluate fraction in fat expansion-type Graves' orbitopathy contained endothelial cell inhibitory activity (at low titers) and stimulatory activity (at high titers), and the latter stimulatory activity was completely neutralized by specific anti-basic fibroblast growth factor antibodies.
Conclusion: Graves' disease suffering globe prolapse secondary to marked orbital fat-expansion had coexisting plasma fibroblast growth factor-inhibitory and -stimulatory autoantibodies. The latter was completely neutralized by anti-basic fibroblast growth factor antibodies.
{"title":"Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy.","authors":"Mark B Zimering, John J Shin, Jennifer D Zaitz, Elkin A Nunez, Andrew G Gianoukakis","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Purpose: </strong>To report a case of orbital fat expansion leading to globe prolapse in a Graves' disease patient undergoing high-dose glucocorticoid therapy. To evaluate the growth factor receptor specificities of plasma autoantibodies in Graves' disease patients who exhibited contrasting subtypes of thyroid-associated ophthalmopathy, i.e. orbital fat expansion-type <i>vs</i>. infiltrative.</p><p><strong>Methods: </strong>Sera from Graves' orbitopathy and control patients with or without Graves' disease were subjected to protein-A affinity chromatography to obtain immunoglobulin G. A (1/50<sup>th</sup> to 1/1600<sup>th</sup>) range in dilutions of the protein-A eluate fraction was incubated for four days at 37 degrees C with bovine pulmonary artery endothelial cells to test for endothelial cell inhibition or stimulation. Growth stimulatory autoantibodies were co-incubated with specific neutralizing anti-insulin like growth factor 1 receptor antibodies or anti-basic fibroblast growth factor antibodies to assess autoantibody specificity in contrasting Graves' orbitopathy subtypes.</p><p><strong>Results: </strong>We observed increased mean endothelial cell growth promoting activity in the protein-A eluates of serum from eighteen patients with active Graves' disease (117 ± 28%, n = 18) compared to mean endothelial cell activity (89 ± 10%, n = 13, P = 0.003) in thirteen adults without Graves' disease. The protein-A eluate fraction in acute infiltrative-type Graves' orbitopathy contained a high titer (> 1:1000) of endothelial cell stimulatory activity which was significantly neutralized by specific monoclonal anti-human insulin-like growth factor 1 receptor antibodies. The protein-A eluate fraction in fat expansion-type Graves' orbitopathy contained endothelial cell inhibitory activity (at low titers) and stimulatory activity (at high titers), and the latter stimulatory activity was completely neutralized by specific anti-basic fibroblast growth factor antibodies.</p><p><strong>Conclusion: </strong>Graves' disease suffering globe prolapse secondary to marked orbital fat-expansion had coexisting plasma fibroblast growth factor-inhibitory and -stimulatory autoantibodies. The latter was completely neutralized by anti-basic fibroblast growth factor antibodies.</p>","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407713/pdf/nihms-1015041.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9591963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A certified reagent kit for newborn screening was transferred on a fully automated dried blood spot platform. The dried blood spot cards are directly eluted and the extract is online guided to tandem mass spectrometry instrument, where the amino acid and acyl carnitine panel is detected. The method takes 2 minutes per sample and requires no human interaction for up to 500 samples. The method is fully standardized through the automation and the usage of only certified consumables and reference material. The manual reagent kit was first modified to fit the automated platform, secondly validated and third, successfully transferred into a routine newborn screening laboratory.
{"title":"Validation of an Automated Extraction Procedure for Amino Acids and Acylcarnitines for Use with Tandem Mass Spectrometry for Newborn Screening","authors":"Stefan Gaugler, Jana Rykl, V. Cebolla","doi":"10.31038/edmj.2019314","DOIUrl":"https://doi.org/10.31038/edmj.2019314","url":null,"abstract":"A certified reagent kit for newborn screening was transferred on a fully automated dried blood spot platform. The dried blood spot cards are directly eluted and the extract is online guided to tandem mass spectrometry instrument, where the amino acid and acyl carnitine panel is detected. The method takes 2 minutes per sample and requires no human interaction for up to 500 samples. The method is fully standardized through the automation and the usage of only certified consumables and reference material. The manual reagent kit was first modified to fit the automated platform, secondly validated and third, successfully transferred into a routine newborn screening laboratory.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47147964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Zimering, John J. Shin, Jennifer D Zaitz, E. A. Nunez, A. Gianoukakis
Purpose To report a case of orbital fat expansion leading to globe prolapse in a Graves' disease patient undergoing high-dose glucocorticoid therapy. To evaluate the growth factor receptor specificities of plasma autoantibodies in Graves' disease patients who exhibited contrasting subtypes of thyroid-associated ophthalmopathy, i.e. orbital fat expansion-type vs. infiltrative. Methods Sera from Graves' orbitopathy and control patients with or without Graves' disease were subjected to protein-A affinity chromatography to obtain immunoglobulin G. A (1/50th to 1/1600th) range in dilutions of the protein-A eluate fraction was incubated for four days at 37 degrees C with bovine pulmonary artery endothelial cells to test for endothelial cell inhibition or stimulation. Growth stimulatory autoantibodies were co-incubated with specific neutralizing anti-insulin like growth factor 1 receptor antibodies or anti-basic fibroblast growth factor antibodies to assess autoantibody specificity in contrasting Graves' orbitopathy subtypes. Results We observed increased mean endothelial cell growth promoting activity in the protein-A eluates of serum from eighteen patients with active Graves' disease (117 ± 28%, n = 18) compared to mean endothelial cell activity (89 ± 10%, n = 13, P = 0.003) in thirteen adults without Graves' disease. The protein-A eluate fraction in acute infiltrative-type Graves' orbitopathy contained a high titer (> 1:1000) of endothelial cell stimulatory activity which was significantly neutralized by specific monoclonal anti-human insulin-like growth factor 1 receptor antibodies. The protein-A eluate fraction in fat expansion-type Graves' orbitopathy contained endothelial cell inhibitory activity (at low titers) and stimulatory activity (at high titers), and the latter stimulatory activity was completely neutralized by specific anti-basic fibroblast growth factor antibodies. Conclusion Graves' disease suffering globe prolapse secondary to marked orbital fat-expansion had coexisting plasma fibroblast growth factor-inhibitory and -stimulatory autoantibodies. The latter was completely neutralized by anti-basic fibroblast growth factor antibodies.
{"title":"Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy.","authors":"M. Zimering, John J. Shin, Jennifer D Zaitz, E. A. Nunez, A. Gianoukakis","doi":"10.31038/edmj.2019313","DOIUrl":"https://doi.org/10.31038/edmj.2019313","url":null,"abstract":"Purpose\u0000To report a case of orbital fat expansion leading to globe prolapse in a Graves' disease patient undergoing high-dose glucocorticoid therapy. To evaluate the growth factor receptor specificities of plasma autoantibodies in Graves' disease patients who exhibited contrasting subtypes of thyroid-associated ophthalmopathy, i.e. orbital fat expansion-type vs. infiltrative.\u0000\u0000\u0000Methods\u0000Sera from Graves' orbitopathy and control patients with or without Graves' disease were subjected to protein-A affinity chromatography to obtain immunoglobulin G. A (1/50th to 1/1600th) range in dilutions of the protein-A eluate fraction was incubated for four days at 37 degrees C with bovine pulmonary artery endothelial cells to test for endothelial cell inhibition or stimulation. Growth stimulatory autoantibodies were co-incubated with specific neutralizing anti-insulin like growth factor 1 receptor antibodies or anti-basic fibroblast growth factor antibodies to assess autoantibody specificity in contrasting Graves' orbitopathy subtypes.\u0000\u0000\u0000Results\u0000We observed increased mean endothelial cell growth promoting activity in the protein-A eluates of serum from eighteen patients with active Graves' disease (117 ± 28%, n = 18) compared to mean endothelial cell activity (89 ± 10%, n = 13, P = 0.003) in thirteen adults without Graves' disease. The protein-A eluate fraction in acute infiltrative-type Graves' orbitopathy contained a high titer (> 1:1000) of endothelial cell stimulatory activity which was significantly neutralized by specific monoclonal anti-human insulin-like growth factor 1 receptor antibodies. The protein-A eluate fraction in fat expansion-type Graves' orbitopathy contained endothelial cell inhibitory activity (at low titers) and stimulatory activity (at high titers), and the latter stimulatory activity was completely neutralized by specific anti-basic fibroblast growth factor antibodies.\u0000\u0000\u0000Conclusion\u0000Graves' disease suffering globe prolapse secondary to marked orbital fat-expansion had coexisting plasma fibroblast growth factor-inhibitory and -stimulatory autoantibodies. The latter was completely neutralized by anti-basic fibroblast growth factor antibodies.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":"3 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46796068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rhizomes of Zingiber officinale (ginger) are used as a spice in many culinary dishes of Bangladesh. Since a number of scientific reports are present on the beneficial effects of raw ginger in Type 2 diabetes mellitus, it was of interest to determine the anti-hyperglycemic efficacy of cooked (boiled) ginger through oral glucose tolerance test (OGTT) in mice. The OGTT results showed that when administered at doses of 50, 100, 200 and 400 mg per kg body weight, methanolic extract of cooked ginger (MEZOC) reduced blood glucose in glucose-loaded mice by 8.0, 20.3, 29.2, and 32.0%, respectively. By comparison, a standard antihyperglycemic drug, glibenclamide, when administered at a dose of 10 mg per kg, reduced blood glucose levels by 48.8%. The results suggest that cooked ginger retains efficiency in lowering blood glucose. Since cooking causes ginger to be less pungent, partaking of ginger in such a manner may prove to be more acceptable to diabetic patients and help control their blood glucose concentrations.
{"title":"Oral Glucose Tolerance Test with Cooked Rhizomes of Zingiber Officinale (Ginger)","authors":"M. A. Mannan, K. Jannat, M. Rahmatullah","doi":"10.31038/edmj.2019311","DOIUrl":"https://doi.org/10.31038/edmj.2019311","url":null,"abstract":"Rhizomes of Zingiber officinale (ginger) are used as a spice in many culinary dishes of Bangladesh. Since a number of scientific reports are present on the beneficial effects of raw ginger in Type 2 diabetes mellitus, it was of interest to determine the anti-hyperglycemic efficacy of cooked (boiled) ginger through oral glucose tolerance test (OGTT) in mice. The OGTT results showed that when administered at doses of 50, 100, 200 and 400 mg per kg body weight, methanolic extract of cooked ginger (MEZOC) reduced blood glucose in glucose-loaded mice by 8.0, 20.3, 29.2, and 32.0%, respectively. By comparison, a standard antihyperglycemic drug, glibenclamide, when administered at a dose of 10 mg per kg, reduced blood glucose levels by 48.8%. The results suggest that cooked ginger retains efficiency in lowering blood glucose. Since cooking causes ginger to be less pungent, partaking of ginger in such a manner may prove to be more acceptable to diabetic patients and help control their blood glucose concentrations.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44785631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zinc is a divalent cation mainly present intracellularly and exerts several indispensible effect therefore maintaining zinc homeostasis is essential. Zinc has a pivotal role in the insulin production, storage and pathways and in carbohydrate metabolism. Plays also an important function in the development of diabetes mellitus and diabetic complications as well. Based on preclinical and clinical studies here we present the most important contributions of zinc to diabetic state and briefly demonstrate why zinc supplementation is beneficial for diabetic patients.
{"title":"Zinc Supplements – Any Benefit in Diabetes?","authors":"I. Télessy","doi":"10.31038/edmj.2019342","DOIUrl":"https://doi.org/10.31038/edmj.2019342","url":null,"abstract":"Zinc is a divalent cation mainly present intracellularly and exerts several indispensible effect therefore maintaining zinc homeostasis is essential. Zinc has a pivotal role in the insulin production, storage and pathways and in carbohydrate metabolism. Plays also an important function in the development of diabetes mellitus and diabetic complications as well. Based on preclinical and clinical studies here we present the most important contributions of zinc to diabetic state and briefly demonstrate why zinc supplementation is beneficial for diabetic patients.","PeriodicalId":72911,"journal":{"name":"Endocrinology, diabetes and metabolism journal","volume":"2017 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69508833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：